viewMaxCyte Inc

MaxCyte teams up with American gene editing specialist to develop new generation of cancer treatments

The company has partnered with Precision Biosciences of the US

MaxCyte's new partner has developed the ARCUS gene editing platform

MaxCyte PLC (LON:MXCT) has negotiated a clinical and commercial licence deal with Precision Biosciences of the US.

Under the terms of the agreement, Precision will use MaxCyte's flow electroporation cell engineering technology alongside its own ARCUS genome-editing platform.  

The plan is to develop the next generation of cell-based therapies for cancer.

READ: MaxCyte inks research agreement with Gilead subsidiary Kite Pharma​

"Precision's therapeutic grade ARCUS editing platform is sufficiently compact and specific to use with a range of delivery systems,” said its chief development officer David Thomson.

“In considering these, we have found MaxCyte's electroporation technology complements our approach to allogeneic T cell manufacturing, which is focused on preserving cell quality throughout the process while maximising overall yield."

Building on earlier deal 

The new tie-up builds on a research and clinical licence agreement the two already had. Under the new terms, MaxCyte will receive undisclosed milestone payments and technology access licensing fees.

"The initiation of this commercial license agreement with Precision, a leader in genome editing with its own proprietary ARCUS technology, signifies a key milestone for MaxCyte and demonstrates the value and versatility of our platform, our intellectual property, and our ability to foster important collaborations with companies generating life-changing gene therapies," said MaxCyte chief executive Doug Doerfler.

The AIM-listed life sciences group’s flow electroporation technology allows cells to be re-engineered efficiently, with high viability and recovery.

Precision will use its ARCUS gene editing tools and the MaxCyte’s breakthrough to transform donor cells into immunotherapies such CAR-T cells.

Quick facts: MaxCyte Inc

Price: 167.5 GBX

Market: AIM
Market Cap: £96.15 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...



MaxCyte Inc gearing up for phase I study of potential cancer breakthrough

Doug Doerfler, chief executive of MaxCyte Inc (LON:MXCT), tells Proactive they're in a strong financial position as they prepare for the launch of a phase I clinical trial of a cancer treatment which helps to deploy the body’s own immune defences to combat strains of the killer...

on 23/1/18

2 min read